0001104659-17-057954.txt : 20170919 0001104659-17-057954.hdr.sgml : 20170919 20170919213151 ACCESSION NUMBER: 0001104659-17-057954 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170915 FILED AS OF DATE: 20170919 DATE AS OF CHANGE: 20170919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CORRIGAN MARK CENTRAL INDEX KEY: 0001250661 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 171093166 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 56 FITZWILLIAM SQUARE CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 1000 CONTINENTAL DRIVE STREET 2: SUITE 600 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 4 1 a4.xml 4 X0306 4 2017-09-15 0 0001641640 Nabriva Therapeutics plc NBRV 0001250661 CORRIGAN MARK 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406 1 0 0 0 Stock Option 2017-09-15 4 A 0 10100 0.00 A 2027-09-15 Ordinary Shares 10100 10100 D The exercise price is $6.86 per share. This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018. /s/ Gary Sender, by power of attorney 2017-09-19